Liftstream is an executive search recruitment company in the life sciences sector
Plaudits, Progress and Partnerships – One important lesson in the push for equality!
Clarus Ventures Strengthens Investment Team with 3 Hires
Clarus Ventures, a life sciences investment firm, has appointed Kiran Reddy and Robert DeBenedetto to Venture Partner, and Lazar Dimitrov to Associate. Based in the firm’s Cambridge, Mass. office, Reddy will focus on both new company formation and risk-sharing partnerships with pharmaceutical companies. DeBenedetto and Dimitrov will be based in Clarus’ South San Francisco, Calif. office.
Scott Morrison Nets Two Board Appointments
Scott Morrison, a retired Ernst & Young Partner, was appointed to the board of directors at Audentes Therapeutics and Global Blood Therapeutics.Watch Full Movie Online Streaming Online and Download
Editas adds CFO and $120m in Series B round
Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the most innovative biopharmaceutical and technology companies.
Executive and Board Director Appointments in Oncology and Rare Diseases
Third Rock Ventures portfolio company, Voyager Therapeutics, a gene therapy player in the field of CNS based out of Cambridge, Mass. have appointed Michael Higgins to the Board of Directors. Mr. Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation, with which Voyager Therapeutics now has a partnership, from 1997 through 2003 in a variety of leadership roles, including vice president of corporate finance and vice president of business development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.
What does it take to reach and succeed at the ‘C’ and Board level?
Liftstream has been collaborating with two organisations to put together a key leadership meeting on gender diversity in biotechnology. The event is based on our published research and we have worked with our network of executives to bring about an incredible panel of industry leaders.
Third Rock Ventures shows promise with early stage investment strategy
Authored by Karl Simpson – April 2013
Executive Recruitment Roundup – July
Authored by Liftstream